BlendCJC-1295 / Ipamorelin (No DAC)
CJC-1295 (without DAC) with Ipamorelin
This research vial combines two growth hormone secretagogues that act through different receptors: CJC-1295 without DAC (also called Modified GRF 1-29), a GHRH receptor agonist, and ipamorelin, a selective ghrelin receptor (GHS-R1a) agonist, at 5 mg each.
Modified GRF (1-29) is the 29-residue active fragment of growth hormone-releasing hormone with four amino-acid substitutions that slow enzymatic breakdown compared with the parent sermorelin sequence. Ipamorelin is a pentapeptide GHRP known in the literature for selectively releasing growth hormone without the ACTH and cortisol responses seen with earlier GHRPs. Because the GHRH and ghrelin pathways converge on the same pituitary cells through different signaling routes, pairing the two is a common design in research on how they interact to shape GH pulses.
PhysIQ Peptides supplies this blend as a lyophilized powder, third-party tested for purity and identity, for in vitro and laboratory research use only.
Choose how to buy
You save $2.50 every reship · ≈ $30.42 saved per year
Auto-delivered • Skip or cancel anytime • Never run out
Your first order ships at the regular price. Every reship after that is 5% off. Pause, change the interval, or cancel anytime.
- Purity
- ≥99%
- Form
- Powder (lyophilized blend)
- Available sizes
- 5/5mg
In this blend
Mechanism of Action
Modified GRF (1-29) binds the GHRH receptor, a Gs-coupled receptor that raises cAMP in pituitary somatotrophs. Ipamorelin binds GHS-R1a, which signals through Gq and intracellular calcium. Published pituitary studies report that co-activation of these two pathways produces a greater growth hormone response than either alone, which is why GHRH analog plus GHRP combinations are studied together.
Research Areas
- ●GHRH and ghrelin receptor co-activation
- ●Growth hormone pulsatility models
- ●Pituitary somatotroph signaling
- ●Secretagogue combination studies
Selected References
- Raun K, et al. Eur J Endocrinol. 1998;139(5):552-561.




